Who
Nirav S. Jhaveri
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Longeveron; Chief Financial Officer, Opus Genetics.
In numbers
- Trades disclosed
- 9
- Buys
- 1
- Sells
- 0
- Bought
- $21K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 12 Feb 2024
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code F | $1,922742 at $2.59 | filing |
| 17 Aug 2026filed 25 Aug 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 17 Aug 2026filed 25 Aug 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 13 Mar 2025filed 17 Mar 2025 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,500 at $0.00 | filing |
| 13 Mar 2025filed 17 Mar 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —52,500 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $9,4388,207 at $1.15 | filing |
| 21 Mar 2024filed 25 Mar 2024 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Bought | $21K10,000 at $2.10 | filing |
| 12 Feb 2024filed 14 Feb 2024 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —210,000 at $0.00 | filing |
| 12 Feb 2024filed 14 Feb 2024 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
News
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood BlindnessIRD · manilatimes.net · 21 Oct 2026Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaIRD · manilatimes.net · 16 Oct 2026Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026IRD · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Nirav S. Jhaveri; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.